Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26773033 | 1.00 | KDM4E (0.52) | KDM4ERAB9AJAK2TYK2JAK1 | |
| SCHEMBL26775594 | 0.92 | GRM5 (0.53) | KDM4ERAB9ATYK2GRM5ALDH1A1 | |
| SCHEMBL30486321 | 0.92 | GRM5 (0.53) | KDM4ERAB9ATYK2GRM5ALDH1A1 | |
| SCHEMBL30486360 | 0.89 | GRM5 (0.44) | KDM4ERAB9AGRM5CCNT1CDK9 | |
| SCHEMBL26773005 | 0.89 | GRM5 (0.44) | KDM4ERAB9AGRM5CCNT1CDK9 | |
| SCHEMBL30486386 | 0.88 | GRM5 (0.43) | KDM4ERAB9AGRM5ALDH1A1 | |
| SCHEMBL26773080 | 0.88 | GRM5 (0.43) | KDM4ERAB9AGRM5ALDH1A1 | |
| SCHEMBL26772978 | 0.87 | JAK2 (0.56) | JAK2TYK2JAK1JAK3SMN1; SMN2 | |
| SCHEMBL30486317 | 0.86 | GRM5 (0.40) | KDM4ERAB9AJAK2TYK2JAK1 | |
| SCHEMBL30486379 | 0.86 | GRM5 (0.40) | KDM4ERAB9AGRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192464-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Origenis GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | KDM4E 688/4885RAB9A 3331/4885JAK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.